anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There are about 60-90% of hemodialysis patients complain of itchy skin, which can cause the sleep quality decline. The important issue of non-invasive acupressure methods to relieve skin itching symptoms and to improve sleep quality are worth explored. Therefore, the research is to explore the effect of acupressure on uremic pruritus and sleep quality among patients receiving hemodialysis. The research method adopts the experimental research method using randomization. The patients receiving the intervention of acupressure are in the experimental group, while those who do not receive it are in the control group. The experimental group will receive the acupressure at the hemodialysis center for a total of 12 weeks, three times a week. The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes. The effectiveness will be evaluated at the fourth week, eighth week and twelfth week. The effectiveness assessment in the study will use the "Visual Analog Scale (VAS)", "5D Pruritus Scale", and "Pittsburgh Sleep Quality Scale". This study uses the pre-test before the implementation of acupuncture, and uses the post-test at week 4, 8, and 12 end of acupuncture. Hopefully, this study may develop a beneficial non-drug care measures to improve the itching symptoms and sleep quality of hemodialysis patients, and to improve their quality of life. If this research result proves that the application of acupressure can be effective, it can not only improve the symptoms of itchy skin and sleep problems in hemodialysis patients, but also hope that can be extended to patients with end-stage renal disease.
Pts will receive pembrolizumab (MK-3475) administered after ureteroscopy/laser ablation in comb w/BCG as initial therapy. Pembrolizumab (MK-3475) will be administered as 400 mg IV infusion at 6-week intervals for 9 doses over a 48-week period, unless there is unacceptable toxicity or other reasons that would warrant the discontinuation of treatment. Pts will receive once-weekly BCG therapy (TICE strain, 50 mg) for 6 consecutive wks as a standard induction course administered through a percutaneous nephrostomy tube in antegrade fashion for patients with high-grade NMI-UTUC, consistent with standard clinical practice. BCG will start on wk 3 after the first infusion of pembrolizumab (400 mg) to allow for initial priming of T cells to further enhance the effects of BCG treatment.
OBJECTIVES: Primary objective: describe rates of 30-days unplanned readmission following outpatient resection of oral cavity cancer. Secondary objective: evaluate for patient and treatment factors associated with readmission.
METHODS: Retrospective, dual-institution cohort study of 2 tertiary care referral centers involving adult patients undergoing resection of oral cavity cancer with plans for same-day discharge. Consecutive sample of 77 patients included. Primary outcome was unplanned readmission to emergency room or inpatient stay in the 30 days following surgery. Comparison testing was used between return and non-return groups.
RESULTS: Among 77 patients treated with outpatient surgery for oral cavity cancer, 19 (25%) returned to the hospital within 30 days. Among the reasons for return, 16 (80%) were directly related to surgery, and 4 (20%) were related to perioperative medical complications not directly related to a surgical site. Among the 25 patients also undergoing sentinel lymph node biopsy with their oral cavity resection, none returned to the hospital for neck-related complications. While most patients could be safely observed and discharged after return to the hospital, 8 patients (10%) required inpatient readmission. No significant differences between return and non-return groups were identified, although there was a trend toward shorter driving distance from hospital for the return group (47.6 miles vs. 69.5 miles, P = 0.097).
CONCLUSION: Unplanned return to the hospital following outpatient oral cavity resection is prevalent and primarily driven by postoperative primary resection site concerns. Among patients selected for same day discharge, no definite population at highest risk of unplanned return was identified.
Subjects will receive EnteraGam® (oral nutritional therapy) + standard of care for COVID-19 for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
The invention relates to non-ribosomal peptides isolated from ontamopathogenic bacteria which have antibiotic activities against protozoan parasites wherein said peptides comprise a C terminal amine group. This group may be as a phenylethylamine, agmatine or tryptamne amino acid. Furthermore, the invention provides novel gene clusters which encode for the non-ribosomal peptide synthetases (NRPS) that mediate the biochemical synthesis of the inventive peptides. The peptides provided by the invention fall under the categories Xenortides, Rhabdopeptides and Mevalagmapeptides. Their use in medicine, specifically in the treatment of a disease caused by a protozoan parasite, such as malaria or sleeping sickness; and/or as insecticidals, for example in plant protection agents is disclosed. Furthermore provided are methods for the production of the peptides of the invention, and the enzymes and. nucleic acids useful for their synthesis in a host cell.
Cancer care is increasingly more complicated due to increasing therapeutic options and is often difficult to access information critical to clinical decisions as a result of the frequency of new studies and decentralization of complex clinical evidence. Patient genomic and other clinical information is critical for making timely and accurate oncology and health care decisions is often in narrative text format scattered across multiple reports and IT systems. It is critical for treatment to encode clinical knowledge pertinent to clinical decision making in an easily accessible form. Discretized information in a digital patient file can assist in creating and selecting relevant therapies based on the body of medical and genomic testing history for a given patient. Discretized information is linked to a pathway execution engine and dynamically updated clinical trial matches. An authoring tool assists in creating pathways for the pathways execution engine to drive care through clinical decision trees.
FIELD: chemistry. ^ SUBSTANCE: invention is aimed at dipyrazole compounds of formula I and their pharmaceutically acceptable salts, where radicals and groups are defined in claim 1 of the formula of invention. Disclosed compounds modulate AMPA and NMDA receptor functioning. A pharmaceutical composition based on formula I compounds and separate dipyrazole compounds are also part of the subject of invention. ^ EFFECT: possibility of using compounds as pharmaceutical agents, mainly for treating psychoneurological diseases. ^ 16 cl, 2 tbl, 39 ex
The investigators will use a commercial available amino acid infusion (Aminosteril hepa 8%, Fresenius Karbi), which is used in clinical application for liver conditioning. It is mainly based on the branched-chained amino acid leucine (13.09 g per 1000 ml). The investigators will combine this with a daily subcutaneous injection of Liraglutide. Liraglutide is a GLP-1 analogue, which achieved meanwhile the FDA approval for weight loss treatment. Initial Liraglutide dosage is 1.2 mg for three days, boosted to 1.8 mg consecutively. Participants receive energy reduced nutrition with 1000 kcal/d.
The object of the present invention is a new method and new products for the therapeutic use of cytokines. The method is based on the sequential administration of a component A (e.g. a biotinylated antibody) able to deliver onto a particular pathologic target a second component B (e.g. avidin), followed by a component able to bind the component B (component C) (e.g. biotin), conjugated with the cytokines. The method permits to increase the local concentration of the modified cytokines (C-cytokines) through the interaction with the 'artificial' receptor B and to cause a local biologic response mediated by 'natural' receptors.
Each subject will receive a single session of exercises with the OCULUS QUEST2 (OCULUS VR, USA) and a hand tracking software (Hand Physics Lab, Holonautic, Switzerland). Brain function monitoring will be made by an EEG system ENOBIO 20 (Neuro-electrics, Spain) positioned over subject head. Intervention consisted of exercises with upper limbs and visual feedback. These activities were projected stereoscopically on VR googles.
This step will retrospectively analyze the medical records of traumatic brain injury adult patients (adult, 350, Hotel-Dieu de Levis) and pediatric patients (406, CHU de Sainte-Justine and Hotel-Dieu de Levis)) randomly selected throughout the year preceding this study in each of the two centers to determine the rate of head CT ordering, the head CT result and the appropriateness of having ordered the head CT based on the CCHR and PECARN criteria. One reviewer will judge the appropriateness of having done a CT scan according to the CCHR and PECARN criteria based on a structured extraction form that will previously be approved by the study's steering committee. To ensure validity, 10% of the analysis will be reviewed by an expert. The reviewer will look at prehospital data collection, triage information, physician's notes, nursing notes and head CT requisition form information to determine if any of the clinical decision rule criteria are present.
There are three main forms of vascular access: peripheral intravenous (PIV), Central venous (CV) and intraosseous (IO). Of the different types of vascular access PIV and CV access have drawbacks when used during resuscitation, because they can be difficult to obtain when patients are volume depleted as in cases of trauma. Attempting CV access has numerous risks with complications occurring in up to 33% of attempts. These include failed placement (22%), arterial puncture (5%), catheter malposition (4%), pneumothorax (1%) and asystolic cardiac arrest (\<1%). Attempting to obtain CV access may also disrupt chest compressions in cases of cardiac arrest. Intraosseous access has been used in scenarios where PIV and CV access is difficult or impossible to obtain. Pharmacokinetic studies and standard practice support the bioequivalence of intraosseous and intravenous administration of common medications. Intravascular depletion does not hinder attempts at IO access, and as the insertion sites are peripheral to the heart, insertion can be done avoiding interruptions in chest compressions. Obtaining proximal humerus interosseous (PHIO) access may also be faster than obtaining both PIV and CV access with a relatively low complication rate. In one survey, complications of IO included difficulty in identifying correct anatomical site (3%), extravasation (3.7%), displacement after insertion (8.5%), and very rarely late complications including compartment syndrome (0.6%), osteomyelitis (0.4%) and skin infection (0.3%).
This evaluation of a newly designed smartphone application (app) for linkage to care, HIV treatment adherence and retention in care, is taking place at five Johannesburg health facilities. Intervention allocation is random with individuals either receiving the smartphone app or standard of care. The trial is motivated by evidence from elsewhere that sending lab results via app acceptable, and loss of patients in need of HIV care can be reduced with mobile Health interventions. There is a growing number of smartphones in South Africa (at the time of baseline assessment, about 40% of the surveyed population had an Android smartphone with data, and the majority of new phones are smartphones). The trial's objectives are: a) Test whether routine linkage to HIV care at public sector services is improved by providing HIV positive clients with a smartphone-enabled app when compared to standard of care; b) Determine HIV treatment initiation rates between intervention and control arm; c) Test the feasibility and acceptability of receiving lab results via app; d) Assess secondary effects from improved participant information, including return rates after falling out of care, participant satisfaction, and rates of repeat blood tests; e) Determine knowledge levels on HIV care; and f) Assess the effect in priority groups for better linkage to care (male HIV cases and HIV positive youth). If data allow, a cost-benefit analysis will also be conducted.
BACKGROUND: Total deep inferior epigastric perforator (DIEP) flap failure is a significant concern in autologous breast reconstruction. Literature on secondary reconstruction options following total flap failure is limited. This study outlines the outcomes of patients who underwent reconstruction post-DIEP flap failure at our institution.
METHODS: We conducted a retrospective analysis of patients receiving autologous breast reconstruction between 2004 and 2021. We aimed to identify causes of total DIEP flap failure, outcomes of revision surgery, and outcomes of secondary breast reconstruction procedures.
RESULTS: From 2004 to 2021, 3456 free flaps for breast reconstruction were performed, with 3270 being DIEP flaps for 2756 patients. DIEP flap failure was observed in 40 cases (1.22%). Bilateral reconstructions had a higher failure rate (2.31%) than unilateral (0.72%). The primary cause was intraoperative complications during flap harvest (18 cases), followed by insufficient arterial perfusion (seven cases). Other causes included postoperative hematoma (seven cases), venous congestion (six cases), and late-onset fat necrosis (two cases). Post-failure, five patients received a second free flap with three cases of repeated flap failure. Twenty patients received implant-based reconstruction with two cases of reconstruction failure, while seven patients received a pedicled latissimus dorsi (LD) flap reconstructions with no cases of reconstruction failure. Eight patients declined further reconstruction.
CONCLUSION: A second free flap post-DIEP failure was associated with a high risk of reconstruction failure, suggesting the need for careful patient selection. Implant-based and pedicled LD flap seem to be reliable secondary reconstruction options.
The invention discloses a clysis liquid for curing the ulcerative colitis. The clysis liquid comprises, by weight, 50-63 parts of houttuynia cordata, 27-35 parts of folium mori, 30-39 parts of phoenix tree leaf, 12-18 parts of shaddock ped, 15-30 parts of cushaw stem and 15-30 parts of rhizoma phragmitis. Retention enema can be realized through the traditional Chinese medicine. The drug does not pass through the stomach and the small intestine so that the influence of gastric acid and digestive enzyme on the drug can be avoided. The drug can be absorbed through the colonic mucosa and directly acts on the focus so that the cure rate of the ulcerative colitis can be improved. No obvious side effect is found, and the cost is low.
The functional impact of impairment to UL following a stroke is critical given the close association between residual strength at the affected UL and performance in activity post-stroke. Exercise is a key element to recovery, even in chronic stroke survivors. However, the response to exercise is quite variable between individuals, reflecting the fact exercise intervention is often based on stroke survivors' clinical score as opposed to their potential for recovery. Accordingly, clients with comparable clinical presentations will often receive a similar intervention, even though they may exhibit very different potential for recovery. Hence, using a suitable prognostic tool of post-stroke recovery to individualize interventions based on individual potential for recovery is essential. One such tool is non-invasive transcranial magnetic stimulation (TMS). TMS elicits motor evoked potentials (MEP), which in turn provide a measure to conveniently assess the integrity of the corticospinal pathway. MEP is currently recognized as a good prognosis for post-stroke potential recovery. Another factor that can improve response to exercise is by modulating the excitability of sensorimotor circuits in the brain by the use of transcranial Direct-Current Stimulation (tDCS). Studies have shown that priming the motor cortex with tDCS before or during an intervention can promote motor recovery in stroke patients.

Goals: 1) To assess if an MEP amplitude stratification, used to guide exercise prescription, can optimize UL function in chronic stroke survivors; 2) To evaluate whether adding tDCS to a more individualized exercise intervention can further improve UL function.

Methods: Participants will be stratified based on their MEPs amplitudes at the affected hand. Within each stratum, participants will be further randomized into two tDCS groups: tDCS real and tDCS sham. The strength training program will target the affected upper limb and will last 4 weeks (3 times/week).The tDCS will be applied to an anodal montage during each training session (12 sessions; 2 mA) for 20 minutes (tDCS real group) or 30 seconds (tDCS sham group).
FIELD: organic chemistry, heterocyclic compounds. SUBSTANCE: invention relates to novel bicyclic derivatives of pyrimidine or its pharmaceutically acceptable salts, method of inhibition of activity of tyrosine kinase in epidermal growth factor receptors, in part, in treatment of patients with cancer diseases, to pharmaceutical composition eliciting activity inhibiting activity of tyrosine kinase in epidermal growth factor receptors and to composition eliciting contraceptive effect. Proposed compounds correspond to the general formula (I)   where 1-2 of radicals A-E mean nitrogen atom and other radicals mean carbon atom, or two adjacent radicals A-E mean heteroatom among the group nitrogen, sulfur atoms and A-E in common with adjacent carbon atoms mean pyridine, pyrimidine, thienyl, pyrrole or imidazole ring; X means groups NH, NHR 5  where R 5  means lower alkyl with 1-4 carbon atoms; n = 0, 1 or 2; R is absent or means hydrogen atom, alkyl with 1-4 carbon atoms, alkoxyl-group with 1-4 carbon atoms, nitro-group, halogen atom, perfluoroalkyl with 1-4 carbon atoms, hydroxyl, amino-group, mono- or dialkylamino-group with 1-4 carbon atoms in each alkyl-group; Ar is phenyl, thienyl; R 1 , R 2 , R 3  and R 4  each is absent independently or means hydrogen atom, alkyl with 1-4 carbon atoms, alkoxyl-group with 1-4 carbon atoms, acyloxy-group with 1-4 carbon atoms, amino-group, mono- or dialkylamino-group with 1-4 carbon atoms in each alkyl-group, acylamino-group with 1-4 carbon atoms under condition that: a) at least one of radicals R 1 - R 4  has value that is distinct from hydrogen atom, lower alkyl with 1-4 carbon atoms or alkoxyl-group with 1-4 carbon atoms; b) if E and B means nitrogen atom then D and A mean carbon atom and R 1  and R 4  are absent; R 3  is hydrogen atom; X is NH; n = 0, 1 or 2; Ar is phenyl substituted with halogen atom, amino-group or hydroxyl or if n = 1 or 2 and Ar is phenyl substituted with halogen atom, amino-group or hydroxyl or if n = 1 or 2 and Ar is thienyl then R 2  has value distinct from hydrogen atom, amino-group or mono- or dialkyl-amino-group with 1-4 carbon atoms in each alkyl moiety, or its pharmaceutically acceptable salt taken in the effective dose. Invention relates to also method of inhibition that involves administration to mammal of the above indicated compound or its pharmaceutically acceptable salt. Proposed compositions have the indicated bicyclic compound taken in effective dose and pharmaceutically or contraceptively acceptable excipient, diluting agent or carrier, respectively. EFFECT: new compounds indicated above, enhanced effectiveness of inhibition, valuable medicinal and pharmacological properties. 54 cl, 17 dwg, 3 tbl, 79 ex
A management system, a management method, a program and an autonomous mobile apparatus. The management system is used for managing the mobile robot as an autonomous mobile device, and comprises a cleanliness setting unit, a command receiving unit, a storage unit and a control unit. The cleanliness setting unit sets cleanliness of the autonomous mobile apparatus. The command receiving unit receives a command of a task executed by the autonomous mobile apparatus. The storage unit stores a database that associates information included in the task with at least one of an operator of the autonomous mobile apparatus, a destination of the autonomous mobile apparatus, a location where the autonomous mobile apparatus passes, and a transported object transported by the autonomous mobile apparatus, and cleanliness of the autonomous mobile apparatus. The control unit controls setting of cleanliness of the host mobile device or processing of the command based on information contained in the database.
Patients of 3 different Allergy Units with clinical history of allergic reactions with peach and with/without reactions with peanut due to sensitization to nsLTP will be informed about the intervention study and potential risks. After obtention of written informed consent, screening phase evaluation will be performed (skin prick tests (SPT), obtention of blood and feces samples and double-blind placebo-controlled food challenges (DBPCFC) with peach and peanut). Participants who meet the eligibility requirements will be randomized in a ratio 1:1 to pectin (apple pectin 10 mg + maltodextrin 5 mg; once daily) or placebo (maltodextrin 5 mg; once daily). The dietary intervention will last 6 months and a follow-up visit in month 3 will be performed. After completing the dietary intervention all participants will be clinically assessed (SPT and DBPCFC) and new blood and feces samples will be collected. Finally, patients who receive the active will be clinically evaluated with DBPCFC to peach and peanut after 6 months of completing the dietary intervention. Also, new blood and feces samples will be obtained.

The main objective is to analyze the clinical efficacy of a pectin dietary supplement administered once a day for 6 months as a treatment for nsLTP allergy in a randomized double-blind placebo-controlled multicenter intervention study. In addition, the investigators will study changes in clinical reactivity to nsLTP and the immunomodulatory effect (immunological humoral and cellular, metabolomics and microbiota profiles). Furthermore, long-term effects of the dietary intervention will be analyzed in participants from the active group (pectin) 6 months after completing the intervention.